IP Library Patent Application 14725110
Patent Application
App. No. 14/725,110

Oxycodone Compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/725,110
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (21)

1 - 79 . (canceled)

80 . A dosage form comprising an active pharmaceutical ingredient comprising oxycodone, 8α,14-dihydroxy-7,8-dihydrocodeinone and less than 25 ppm of 14-hydroxycodeinone.

81 . The dosage form of claim 80 , which is a tablet.

82 . The dosage form of claim 80 , which is a capsule.

83 . The dosage form of claim 80 , which is a sustained release dosage form.

84 . The dosage form of claim 80 , which comprises particles of the active pharmaceutical ingredient.

85 . The dosage form of claim 84 , wherein the particles have a diameter of from about 0.1 mm to about 2.5 mm.

86 . The dosage form of claim 85 , wherein the particles have a diameter of from about 0.5 mm to about 2 mm.

87 . The dosage form of claim 80 , wherein the active pharmaceutical ingredient is oxycodone hydrochloride.

88 . The dosage form of claim 87 , which comprises from about 10 mg to about 320 mg of oxycodone hydrochloride.

89 . The dosage form of claim 80 , which contains about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 80 mg, about 100 mg, or about 160 mg of the active pharmaceutical ingredient.

90 . A dosage form comprising an active pharmaceutical ingredient comprising oxycodone, 8α,14-dihydroxy-7,8-dihydrocodeinone, less than 5 ppm of codeinone, and less than 25 ppm of 14-hydroxycodeinone.

91 . The dosage form of claim 90 , which is a tablet.

92 . The dosage form of claim 90 , which is a capsule.

93 . The dosage form of claim 90 , which is a sustained release dosage form.

94 . The dosage form of claim 90 , which comprises particles of the active pharmaceutical ingredient.

95 . The dosage form of claim 94 , wherein the particles have a diameter of from about 0.1 mm to about 2.5 mm.

96 . The dosage form of claim 95 , wherein the particles have a diameter of from about 0.5 mm to about 2 mm.

97 . The dosage form of claim 90 , wherein the active pharmaceutical ingredient is oxycodone hydrochloride.

98 . The dosage form of claim 97 , which comprises from about 10 mg to about 320 mg of oxycodone hydrochloride.

99 . The dosage form of claim 90 , which contains about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 80 mg, about 100 mg, or about 160 mg of the active pharmaceutical ingredient.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: CHAPMAN, ROBERT; RIDER, LONN S.; HONG, QI; KYLE, DONALD; KUPPER, ROBERT
To: EURO-CELTIQUE S.A.
Reel/Frame 040033/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 040034/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 040034/0442 →